story of the week
Sulfonylureas as Second-Line Drugs in Type 2 Diabetes Associated With Increased Risk of Cardiovascular and Hypoglycemic Events
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
BMJ: British Medical Journal
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Sulfonylureas as Second Line Drugs in Type 2 Diabetes and the Risk of Cardiovascular and Hypoglycaemic Events: Population Based Cohort Study
BMJ 2018 Jul 18;362(xx)k2693, A Douros, S Dell'Aniello, OHY Yu, KB Filion, L Azoulay, S SuissaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.